ESR1 and breast carcinoma: Future work will identify who would gain the most benefit fromPR or AR-targeted drugs for the treatment of specific ER+ breast cancercases, a hypothesis that is supported by a wealth of clinical data showing that PRagonists have efficacy in breast cancer patients selected only based onER+ status (74, 75, 76, 77, 78, 79, 80, 81, 82).